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While the COVID-19 pandemic continues to spread rapidly, resulting in considerable
morbidity and mortality worldwide, multiple efforts are being made by the international
scientific community to understand the pathogenesis of the viral infection and its clinical
outcome. Older age and comorbidities have consistently been reported as risk factors
for unfavorable prognosis, with cardiovascular disease accounting for up to 10 % of
comorbid conditions among the infected patients. An understanding of the mechanism
underlying the effect of this infection on patients with cardiovascular disease is essential
to manage and improve clinical strategies against the disease in that population. In this
review, we summarize the impact of COVID-19 on patients with underlying cardiovascular
conditions and the cardiac implications of known and emerging therapeutic strategies.
Our future effort will aim to further elucidate how the type and severity of the cardiac
disease, with particular regard to Congenital Heart Disease, influences the prognosis
and the outcome of the viral infection.
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INTRODUCTION
COVID-19 is a severe acute respiratory illness caused by a new coronavirus (SARS-CoV-2), which
is recognized as the third human pathogen causing a severe respiratory syndrome after SARS-CoV
and Middle East Respiratory Syndrome (MERS)-CoV1 (1, 2).
Although most infected people only show mild-to-moderate respiratory symptoms or nothing
at all, up to 10% of infected individuals manifest the complete acute respiratory distress syndrome
(ARDS) of COVID-19 (3, 4). Pre-existing medical conditions and comorbidities, along with the
advanced age, are considered key factors for the outcome of the disease (3, 5, 6).
CARDIOVASCULAR INVOLVEMENT IN THE COVID-19 PANDEMIC
Multiple studies have shown that patients with underlying cardiovascular disease (CVD) such
as hypertension and coronary artery disease are more likely to suffer from a severe COVID-19
infection that requires ICU care (3, 7, 8). In addition, data from all past influenza pandemics, (i.e.,
the 1918 flu, SARS, and MERS) revealed that cardiovascular events surpassed all other causes of
mortality, including superimposed pneumonia (9–11).
As a matter of fact, there seems to be a particular interplay between the 2019 novel coronavirus
and the cardiovascular system. The already increased metabolic demand and the reduced/impaired
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cardiovascular reserve in CVD patients could explain the
association between the two pathological conditions (12).
The overwhelming immune inflammatory response and
the subsequent cytokine storm that hits the heart as the
delayed consequence of the SARS-CoV-2 infection contributes
to worsening the precarious cardiac status via the mechanism
of inflammation-induced heart failure. This includes endothelial
dysfunction due to imbalance between ROS production and
NO reduction, left ventricular remodeling, and fibrosis by
differentiation of fibroblasts into myofibroblasts following
transforming growth factor beta (TGFβ) secretion by monocytes
(13, 14).
In addition, the heart might indirectly suffer from pulmonary
injury caused by direct viral infection of lung epithelia via ACE2,
which causes pulmonary damage and hypoxemia and, in turn,
may lead to further end-organ dysfunction, such as oxidative
stress-induced injury in the heart (3, 15).
A direct viral infection of the cardiomyocytes is also plausible
due to the presence of ACE2 in the heart. Previous SARS
epidemic post-mortem analysis showed the presence of viral
genome in heart biopsies; however, this evidence has not yet been
demonstrated in SARS-CoV-2 infection (16).
It is likely that, to different extents, each of these mechanisms,
or a combination of them, plays a role in the cardiac injury
that manifests in the late hyper-inflammatory phase of the
viral infection. The high levels of cytokines detected during
the advanced stage of the illness (IL-6, IL-2, IL-7, TNF-α, and
interferon-γ) correlates with elevated levels of biomarkers of
cardiac injury, both of which increases are associated with
worse prognosis (5–7, 17–19). For example, the elevation of
troponin I (TnI) and brain-type natriuretic peptide (BNP)
biomarkers was found to be a predictor of in-hospital death
(5, 7, 8, 20, 21). Elevated inflammatory markers also correlate
with electrocardiographic abnormalities, arrhythmias, and blood
pressure disorders, whose incidence has been reported to be
significantly higher among those requiring ICU care (44.4 vs.
6.9%) compared with those treated in non-ICU beds (18, 22).
Table 1 summarizes the cardiovascular comorbidity and cardiac
injury in COVID-19 patients.
COVID-19 AND ADULT CONGENITAL
HEART DISEASE
To date, there is no evidence on COVID-19 complications in
patients with congenital health disease (CHD). To the best of our
knowledge, only one multi-center, observational Italian study has
assessed, through a nationwide survey, the clinical characteristics
and outcomes in patients with CHD affected by COVID-19 (23).
Out of the 76 patients included in the study, nine patients (seven
adults, two children) had a history of CHD, including atrial septal
defect, ventricular septal defect, tetralogy of fallot, coarctation of
aorta, and pulmonary atresia. Cardiovascular complications, in
the form of heart failure, arrhythmias, and myocardial injury,
were mainly observed in the CHD-COVID-19+ group; however,
no critical respiratory outcome and no virtual death were
observed. Although the authors concluded that the overall mild
clinical courses observed in the current panorama of literature
reporting an association between cardiovascular risk factor and
higher fatality rate in COVID-19 patients were rather reassuring,
more randomized trials involving larger populations are needed.
In the absence of wider and conclusive data, the Adult
Congenital Heart Association and the British Congenital Cardiac
Association have included this patient population among the at-
risk group, given the profound impact of the virus on the heart
of CVD patients. In particular, complex CHDs, such as cyanotic
heart defects, single ventricle, pulmonary atresia, and truncus
arteriosus, have been listed as higher risk conditions on the basis
of decreased functional reserve (24, 25). Therefore, it is strongly
advised that these patients take great care in preventing infection,
adopting social distancing measures, frequent handwashing,
and proper use of personal protective equipment. Diagnosis
of suspicious cases in CHD individuals is similar to in the
general population; however, further diagnostic methods, such
as chest CT, might be warranted in addition to the canonical
nasopharyngeal swab and RT-PCR tests (26). Furthermore, the
evaluation of cardiac injury markers could be important for the
management of COVID-19-positive CHD patients showing signs
of acute coronary syndrome (i.e., chest pain), arrhythmias, and
myocardial injury (i.e., abnormal ECG), for which the use of
supplemental oxygen might not be sufficient. The opportune use
of mechanical ventilation, fluid resuscitation, and extracorporeal
membrane oxygenation could be of additional support in such
cases, as it has proved to be successful in critically ill patients
(3, 27).
COVID-19 AND THE PEDIATRIC CHD
POPULATION
No studies have reported, as yet, on the correlation between
COVID-19 and children with CHD. The pediatric population
seems, overall, to be less vulnerable to COVID-19 than adults.
A restrained cytokine storm as a result of a not fully developed
adaptive immune response, together with less functional ACE2,
which makes SARS Cov2 less infectious, has been suggested as
the main mechanism underlying the reduced susceptibility of
children (28). Nevertheless, young children and infants appear
to be more susceptible to developing severe disease than older
children (4, 29). A case report from China described the case of
a COVID-19-positive 55-day-old infant with pneumonia, liver
injury, and heart damage, as revealed by abnormal myocardial
zymogram and occasional arrhythmias (30). In another small
case series of critically ill patients with COVID-19, the case of
a 13-month-old child who developed heart failure, together with
multiple organ failure was reported (31). Multiorgan failure was
also the cause of the death of a 10-month-old child with a history
of intussusception (32).
As seen in the adult population, comorbidity is also a critical
factor for SARS-CoV-2 infection, and children with underlying
disease are more likely to be more susceptible to COVID-
19. A retrospective study carried out in China involving 25
pediatric patients showed that the most aggressive COVID-
19-related infection was detected in two patients previously
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TABLE 1 | Characteristics of COVID-19 patients with cardiovascular disease.
References Patients (n) Age Cardiovascular comorbidity CHD history Cardiac injury Death
Yang et al. (3) 52 30–80 years Chronic cardiac disease (5 pt) NA Acute cardiac injury (high Troponin I) Yes (3 pt)
Zhou et al. (7) 191 46–67 years Hypertension 58pt Coronary artery disease (15 pt) No Heart failure, acute cardiac injury Yes (39 pt)
Arentz et al. (8) 21 43–92 years Congestive heart failure (9 pt) No Cardiomyopathy NA
Sabatino et al. (23) 76 1–52 years Hypertension (5 pt) Prev. cardio-embolic stroke (2 pt) Yes (9 pt) Heart failure, arrhythmias, myocardial injury No
operated for CHD (33). In another retrospective study analyzing
the clinical, laboratory, and chest CT features of 20 pediatric
inpatients with COVID-19 in Wuhan, it was reported that
7 out of 20 hospitalized patients had a previous history of
congenital or acquired disease, with two cases having a history
of atrial septal defect surgery. However, the authors did not
report whether the pre-existing conditions resulted in a worse
or longer prognosis, which is a limitation of the study (34).
Interestingly, the laboratory findings showed that in addition
to the increased levels of common inflammatory markers and
abnormal CT chest also reported in adults, almost all the cases (16
out of 20, 80%) presented elevated levels of procalcitonin (PCT),
which is not common in adult patients and, therefore, worth
further investigation. PCT is a diagnostic factor more specific for
bacterial infections, which indeed was found in half the analyzed
patients, suggesting that routine antibacterial treatment might be
considered in such pediatric patients (35).
In the absence of any available data on COVID-19 in children
with CHD, this population has been categorized, as in adults, as
a group that is particularly vulnerable to becoming unwell with
respiratory infections, including COVID-19 (24). Therefore, the
same particular care must be taken for this population, especially
for those affected by cyanotic heart conditions (oxygen saturation
< 85% at rest), which are likely to worsen in a hypoxemic
pulmonary circulation setting.
Based on a literature review of published and unpublished
data, a team of experts at Alder Hey Children’s Hospital,
Liverpool, has set up some guidance for the clinical management
of children admitted to hospital with proven COVID-19 (36).
As a guideline for the treatment of hypoxic children
developing respiratory failure and requiring respiratory support,
the authors recommend that patients receive low flow nasal
cannula (LFNC) oxygen rather than high flow nasal cannulae
(HFNC) in order to reduce droplet spread of the virus. However,
if children are hypoxic despite LFNC, then HFNC can be tried. In
addition, although there is no evidence in the literature regarding
blood gases and these should not be routinely used, their use
is justified in children who, despite administration of HFNC,
require further respiratory support.
Clinical studies enrolling the pediatric CHD population are
needed in order to collect data to better understand outcomes
in this population. In the field of cardiac surgery, few surveys
have been developed in the UK in order to explore how the
surgical case mix and to link this information with a national
database with perioperative outcomes as a primary endpoint
(37). Meanwhile, the patient waiting list has changed during this
pandemic both in adults and in congenital cardiac surgery.
Concerning data have emerged in the last few
weeks regarding an apparent rise in the number of
children of all ages presenting with a multisystem
inflammatory state, typical of Kawasaki disease (KD),
requiring intensive care across the UK and several other
countries (38).
KD is a rare acute pediatric vasculitis, with coronary artery
aneurism (CAA) as its main complication (Figure 1). One
pronounced feature of KD is persistent fever, accompanied
with exanthema, lymphadenopathy, and changes to
mucosae (39). Prompt diagnosis and treatment with
intravenous immunoglobulin (IVIG) results in complete
recovery of patients in most cases, preventing possible CAA
complications (40).
Some of the children that, in the present circumstance,
developed KD-like symptoms had tested positive for COVID-
19, whilst others had not, suggesting that the critical systemic
toxic shock symptoms could be related to another unidentified
infectious pathogen. However, even though the relationship of
KD to COVID-19 is not yet defined, there is growing concern
that SARS-CoV-2 infectionmight be linked with the concomitant
inflammatory syndrome that is affecting some young children.
Congruent with this notion are the data from an Italian cohort
study, reporting the case of ten children with Kawasaki-like
disease, some of which required fluid resuscitation and inotropic
support, and all of whom tested positive for SARS-CoV-2 either
by swab or serology test (41).
An association between the novel virus and KD in
children is further supported by a French study describing
a case series of major systemic inflammation and acute
myocarditis following SARS-CoV-2 infection in 20 critically
ill children (42). In all of the patients, a remarkably high
rate of IgG and IgA was detected, suggesting a post-
viral immunological reaction impacting the myocardium. The
significant reduction of inflammatory biomarkers and the cardiac
function improvement following IVIG further reinforce the
hypothesis of a SARS-CoV-2 post-infective disease. The cardiac
involvement of pediatric inflammatory multisystem syndrome
associated with SARS-CoV-2 was also reported by another
single-center retrospective study conducted at Birmingham
Children’s Hospital (43). All of the pediatric patients presented
impaired left ventricular function, valve regurgitation, and/or
coronary artery involvement, which reflects a significantly
higher cardiac involvement compared to the Italian and
French series.
Although all of these studies suggest that the emerging
severe multisystem inflammatory disease might be one of the
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FIGURE 1 | Angiographic pictures of very large saccular aneurysms (red arrows) in the left coronary (a) and right coronary (b) systems in a 6-month-old patient
diagnosed with Kawasaki disease.
unknown clinical post-infective complications of the SARS-
CoV2 infection, long-term follow-up and further research are
needed to understand the immunopathology and the potential
mechanistic link between COVID-19 and Kawasaki disease.
Table 2 summarizes the characteristics of the studies focused
on cardiovascular involvement in COVID-19-affected children.
THERAPEUTIC APPROACH AND THE
CARDIAC CONCERN
Since the spread of the pandemic in January 2020, there has been
a rapidly growing number of clinical trials; however, to date, no
definitive therapies, other than supportive care, are available. An
extensive review of the therapeutic agents under investigation for
the treatment of COVID-19 is beyond the scope of this review.
We, therefore, intend to focus on the cardiac involvement of the
therapeutics that have been employed or are under investigation
as options for COVID-19 treatment (Table 3).
Antivirals, such as Lopinavir and Ritonavir, were reported
to have the potential to treat SARS infections; however, no
efficacy in COVID-19 patients has been proven so far (44, 45).
In addition, many antiviral drugs are known to cause cardiac
insufficiency, arrhythmia, or other cardiovascular disorders
(46). Cardiovascular toxicity (conduction abnormalities and
long QT syndrome) is also associated with the antimalarial
agents chloroquine and hydroxychloroquine, which have been
proposed as off-label agents to treat SARS-CoV-2 infection
after proving effective against SARS CoV-2 in vitro (47, 48).
Preliminary results from clinical trials on COVID-19 patients
remain not fully convincing, and further evaluation is needed
(49). Therefore, the use of these agents during treatment of
COVID-19 conditions must be carefully considered and the risk
of cardiac toxicity closely monitored in patients with pre-existing
cardiovascular conditions.
The use of corticosteroids, although not recommended in the
first phase of the infection due to the side effect of worsening
the lymphocytopenia that manifests in the acute disease
progression, can be justified in the later hyperinflammatory stage.
Furthermore, lower incidence of myocardial infarction among
patients with pneumonia was associated with corticosteroid
treatment, and glucocorticoid treatment proved to be lifesaving
for a 37-year-old man with fulminant myocarditis (50).
There has been a tremendous amount of speculation
surrounding the potential adverse effect of angiotensin-
converting enzyme inhibitors (ACEi) and angiotensin receptor
blockers (ARS) in CVD patients with COVID-19. In animal
models, these drugs increased cardiac ACE2 expression after
chronic treatment (51). Though this effect, on the one side,
would increase the number of receptors available for SARS-
CoV-2 binding, on the other side, it might be protective against
lung and heart injury as a consequence of the reduction of
angiotensin II levels and increased production of the tissue
protector Angiotensin 1–7. In fact, following SARS-CoV-2
binding to ACE2, the latter is internalized and degraded;
therefore, COVID-19 is characterized by ACE2 depletion and
endothelial dysfunction. While more studies are needed to
elucidate the effect of angiotensin-converting enzyme inhibitors
and angiotensin receptor blockers in COVID-19 CVD patients,
the American Heart Association and the European Society
of Cardiology have recommended the continuation of RAAS
inhibitors for patients currently taking them for indications for
which these agents are known to be beneficial (52, 53).
ADVANCED TREATMENT: CELL THERAPY
Among the many clinical trials currently ongoing (over 80
at the time of this review) that aim to find a therapeutic
solution to the COVID-19 pandemic, there are some emerging
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TABLE 2 | Review of COVID-19 pediatric patients and cardiovascular involvement.
References Patients
(n)
Age CHD history Cardiovascular symptoms Cardiovascular tests Therapy
Cui et al.
(30)






No Heart failure (1pt) Non-specific for CV disease Plasmapheresis and oxygen
Lu et al.
(32)












Yes (2 pt) Abnormal EGC Procalcitonin NA
Verdoni
et al. (41)








15 6–11 years No Kawasaki disease, abnormal EGC,
LV dysfunction, atrioventricular valve
regurgitation
Cardiac enzymes i.v immunoglobulin, aspirin,
methylprednisolone
TABLE 3 | Cardiac involvement of medications used in COVID-19 patients.
Medication Cardiac concern and recommendation
Antivirals No proven efficacy on COVID-19 patients.
Some of these agents can cause cardiac
insufficiency, arrhythmias, or other
cardiovascular disorders.
Antimalarial Limited human data to support
effectiveness in humans. Some of these
medications can prolong the QT interval;
this should be taken into consideration,
especially in patients on other
QT-prolonging agents.
Corticosteroids Can cause or exacerbate existing
lymphocytopenia. Not recommended in
the first phase of the infection; can be
favorable in the later hyperinflammatory
stage.
ACEi/ARB Theoretical concern because of potential
upregulation of ACE-2. However, no data
support interaction with the disease.
Suggest continuing the medication.
studies involving cell therapy. Such trials are motivated by the
rationale that cells with immunomodulatory properties, along
with regenerative capacity, might be beneficial in treating the
infection. Based on these peculiar features, cell-based therapy has
been incorporated into treatment plans for a number of diseases,
including pulmonary and cardiovascular diseases, and immune-
mediated inflammatory conditions, such as graft-vs.-host disease
(GVHD) and systemic lupus erythematosus (54–56).
Mesenchymal stem cells, somatic progenitor cells, appear to
be an attractive candidate for a cell-based therapeutic approach
in COVID-19 owing to their powerful immunomodulatory
ability, which might be crucial in preventing or attenuating the
deleterious cytokine storm to the lung and, as a result, to multiple
end-organs (57).
In addition, their differentiation and regenerative capacity,
through the release of trophic factors (IL-10, VEGF, FGF,
etc.), could improve the lung microenvironment, where they
accumulate after intravenous infusion, and exert their effect by
protecting epithelial cells, preventing pulmonary fibrosis, and
improving alveolar cell function (54, 58). Importantly, MSCs do
not express ACE2 on their cellular surface, indicating that these
cells are free from COVID-19 infection (59) (Figure 2). It is,
however, not clear if this cell type, as well as other low ACE2
expressing cells, can be infected through other entry receptors.
Two recent Chinese studies have investigated the effect
of intravenous administration of clinical-grade human MSCs
into patients with COVID-19. In the study by Dr. Zhao
and collaborators, the seven patients positive for SARS-CoV-2
with pneumonia recovered from all the symptoms (high fever,
shortness of breath, and low oxygen saturation) by 2–4 days
after receiving the MSC infusion. In addition, chest CT imaging
demonstrated that chest pneumonia infiltration significantly
subsided, and also pro-inflammatory cytokines reduced (59).
The second study is a case report of a critically ill 65-year
old Chinese woman infected with COVID-19 whose conditions
improved after the infusion of allogeneic umbilical cord-
derived MSCs. Despite the significant clinical outcome and good
tolerance, conclusions cannot be drawn on the base of a single
case, especially given that the MSC treatment was superimposed
on other therapies, including antivirals, immunoglobulin, and
corticosteroids (60).
Whether injected MSCs would have a beneficial effect on
an injured heart as a consequence of the viral infection is
unclear. However, it is reasonable to hypothesize that, given
the modality of systemic administration, the majority of MSCs
would accumulate in the pulmonary vascular bed where they
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FIGURE 2 | Possible mechanism of THE therapeutic effect of MSCs in COVID-19 treatment. MSCs might exert their beneficial effect through immunomodulatory
capacity by interacting with immune cells and, in turn, avoid the cytokine storm that causes lung, and multiple organ injury. Furthermore, owing to their regenerative
properties, they could improve the lung microenvironment through the release of trophic factors that protect epithelial cells and improve alveolar cell function. A direct
effect of MSCs on the heart in this setting is uncertain. Adapted from References (15, 27).
are cleared within 24–48 h, as demonstrated by tracking studies
using labeled MSCs. Therefore, the amount of cells reaching the
heart might not be significant enough to support myocardial
regeneration (61).
Nevertheless, concerns regarding the safety of these
infusions must not be underestimated, as the potential
thrombogenic risk associated with their intravenous
administration cannot be excluded. Activation of coagulation
was reported in several transplanted patients and could
be linked to the expression of tissue factor (TF) on MSCs
that, when in contact with blood, initiates coagulation
(62). Embolus formation from transplanted MSCs in the
lungs of small and large animals has been described, as
has lethal pulmonary thromboembolism following the
administration of adipose-derived MSCs in some patients
(62, 63).
The vessel blockage could provide further hypoxic stress to
the lung and related tissues, especially those with high-oxygen
consumption and nutritional demand, such as the myocardium,
which can ultimately result in additional cardiac damage.
Despite the paucity of pre-clinical and clinical data showing
an effective benefit of MSCs on COVID-19 patients, the number
of MSC-based clinical trials aimed at exploring the therapeutic
potential of cell treatment for SARS-CoV-2-infected patients is
rapidly increasing.
Researchers and clinicians in the United States have urged
the US administration and COVID-19 task force to minimize
regulatory burden by all agencies so that umbilical cord-derived
MSCs can be considered for compassionate use in critically ill
COVID 19 patients who are not responding to conventional
therapies in order to reduce morbidity and mortality in the
United States (64).
A team of scientists led by Dr. Ricordi at the Cell Transplant
Center, University of Miami Miller School of Medicine,
has recently been granted immediate US Food and Drug
Administration (FDA) authorization for a 24-patient clinical trial
to test the safety and exploratory efficacy of umbilical cord-
derived mesenchymal stem cells (UC-MSCs) to prevent the life-
threatening lung inflammation that accompanies severe cases of
COVID-19 (65).
Based on the same principle as expandedMSCs, cardiosphere-
derived cells (CDCs) have been proposed for the treatment
of critically ill COVID-19 patients (15). CDCs are stromal
progenitor cells isolated and grown from human heart tissue,
with proven in vivo myocardial protection, anti-inflammatory
effects, and immunomodulatory properties (15, 66).
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Professor Marban, a pioneer of the CDC technique, has
recently proposed the (CS)3 trial, aimed at enrolling critically
ill patients with pneumonia and signs of lymphocytopenia and
cytokine storm and evaluating the effect on cardiac and immune
function, as well as the outcome on mortality, length of stay in
ICU, and duration of ventilatory support.
PERSPECTIVES
Despite the promise and excitement surrounding cell therapy in
COVID-19 disease, precautions must be taken to not create false
hopes, as we witnessed in the past when stem cells were sold
directly to patients as “cures” without systematic clinical trials to
test for safety and effectiveness.
Rigorous clinical trials are needed, which must be designed to
strict standards, including detailed information as to inclusion
and exclusion criteria, comorbidities, dose and source of cell,
timing of administration relative to onset of disease, recognized
endpoints, and follow up.
The same caution must accompany the results and
interpretation of all trials that are being conducted worldwide
to avoid declaration of unproven efficacy such as where drugs
have been presented as “game changers” despite showing only
tentatively positive results.
SARS-CoV-2 is a new pathogen, and its long-term effects
are unknown. Organ complications might persist even after
the resolution of acute illness. The previous SARS epidemic
is informative as to the possible long-term consequences
of the disease. Long-term follow-up studies showed that,
12 years after contracting the virus, patients who recovered
from SARS-CoV in 2003 were affected by cardiovascular
abnormality, serum metabolic disorders, and pulmonary
fibrosis (67, 68).
In the uncertain scenario of the COVID-19 pandemic, the
mobilization of the scientific and medical community has
been immensely inspiring. It is important that speculation and
political pressure to accelerate approvals for treatments that are
not supported by sound science do not take over the communal
research effort toward understanding in detail the biology of
SARS-CoV-2 and developing an effective vaccine, together with
new therapies with proved safety and efficacy.
More studies are also needed to evaluate the effect of SARS-
CoV-2 and potential therapies on populations classified as risk
groups but with no clear evidence on the consequence of the
COVID-19 disease. Adult and pediatric patients with congenital
heart defects are among these groups. As a team involved in
CHD research and surgery, we are aiming at analyzing blood
and urine samples that we have been collecting from patients
undergoing routine corrective heart surgery and correlating the
presence of COVID-19, whenever ascertained, with effects on
cardiac biomarkers, function, and clinical outcome. The study
aims to further elucidate whether the type and severity of
CHD have an impact on the expression of specific markers
and clinical outcomes in COVID-19 patients and whether these
could be predictive factors of the progression of the disease. This
knowledge would provide effective tools for the management of
specific CHD conditions in the presence of COVID-19 and other
hyperinflammatory syndromes of viral or non-viral etiology that
might affect the heart and vasculature.
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